Adding the MET Inhibitor Savolitinib to Osimertinib was Beneficial for Certain Pretreated Lung Cancer Patients in TATTON Trial
ATLANTA – Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients...